Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Qinyao Zhu
Observed names:
Q. Zhu,
Qinghao Zhu
Institution:
Zhongyuan University of Technology
Observed institutions:
Zhongyuan University of Technology,
Genentech,
Lilly (China),
Suzhou City University,
Shenyang University of Chemical Technology
ORCID:
0009-0008-4711-5709
Observed ORCID:
0009-0008-4711-5709
OpenAlex ID:
A5013966725
DNA origami assembled spheroid for evaluating cytotoxicity and infiltration of chimeric antigen receptor macrophage (CAR-M)
2024
·
Qinyao Zhu
, Xiaofang He
, et al.
·
Communications Biology
·
13
PDF
Tumor micro-environment induced TRAIL secretion from engineered macrophages for anti-tumor therapy
2024
·
Qinyao Zhu
, Xin Huang
, et al.
·
Cellular Immunology
·
8
PDF
Morinda officinalis saponins promote osteogenic differentiation of human umbilical cord-derived mesenchymal stem cells via the BMP-SMAD signaling pathway
2024
·
Jian Zhou
, Fanru Zhou
, et al.
·
American Journal of Translational Research
·
8
PDF
Structural Basis for the Inhibition of SARS-CoV-2 Mpro D48N Mutant by Shikonin and PF-07321332
2023
·
Zhenyu Zhao
, Qinyao Zhu
, et al.
·
Viruses
·
5
PDF
1556P Preliminary clinical results of CAR-macrophage in metastatic HER2-low expressing and HER2-positive solid tumors
2025
·
Z. Han
, X. Yin
, et al.
·
Annals of Oncology
·
2
813P Time to development of central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with vemurafenib (V) + cobimetinib (C): Updated results from the phase III IMspire150 study
2022
·
K. Lewis
, C. Robert
, et al.
·
Annals of Oncology
·
2
Research on the Integration of Ideological and Political Education into Cybersecurity Postgraduate Courses: A Big Data-Driven Approach
2025
·
Long Zhang
, Bing Xia
, et al.
·
Communications in computer and information science
·
1
Structural basis for the inhibition of the HCoV-NL63 main protease Mpro by X77
2024
·
Jie Xu
, Qinyao Zhu
, et al.
·
Biochemical and Biophysical Research Communications
17P Safety and tolerability of sintilimab (sint) combination therapy in patients with advanced or recurrent non-small cell lung cancer (NSCLC): Pooled safety analysis of ORIENT 11 and ORIENT 12 studies
2022
·
G. Gao
, Y. Zhao
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
9
Citation count:
39
H-index:
4
I10-index:
1
Year
Topic
Type